Cortot A B
Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, 44, Binney Street, D820, Boston, MA 02115, États-Unis. alexis
Rev Pneumol Clin. 2010 Dec;66(6):367-74. doi: 10.1016/j.pneumo.2010.07.017. Epub 2010 Dec 3.
Molecular targeted agents represent a major breakthrough in the treatment of non-small cell lung cancer. Among these agents, Epidermal Growth Factor Receptor (EGFR) inhibitors are probably the more important so far. Whether inhibition is obtained by targeting the tyrosine kinase of the receptor (gefitinib or erlotinib) or by using a monoclonal antibody (cetuximab), the place of these treatments will increase in the next years. This article details the role of EGFR in lung carcinogenesis and the main therapeutic approaches used to inhibit EGFR activity. The results of the major clinical trials evaluating these agents are also discussed.
分子靶向药物代表了非小细胞肺癌治疗的一项重大突破。在这些药物中，表皮生长因子受体（EGFR）抑制剂可能是目前更为重要的药物。无论通过靶向受体的酪氨酸激酶（吉非替尼或厄洛替尼）还是使用单克隆抗体（西妥昔单抗）来实现抑制作用，这些治疗方法在未来几年的应用将会增加。本文详细阐述了EGFR在肺癌发生中的作用以及用于抑制EGFR活性的主要治疗方法。同时也讨论了评估这些药物的主要临床试验结果。
